首页> 外文期刊>Neuro-Oncology >International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
【24h】

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

机译:国际回顾性研究超过1000名成人间变性少突胶质细胞瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Treatment for newly diagnosed anaplastic oligodendroglial tumors is controversial. Radiotherapy (RT) alone and in combination with chemotherapy (CT) are the most well studied strategies. However, CT alone is often advocated, especially in cases with Ipl9q codele-tion. We retrospectively identified 1013 adults diagnosed from 1981-2007 treated initially with RT alone (n = 200), CT + RT (n = 528), CT alone (« = 201), or other strategies {n = 84). Median overall survival (OS) was 6.3 years and time to progression (TTP) was 3.1 years. Ipl9q codeletion correlated with longer OS and TTP than no lp or 19q deletion. In codeleted cases, median TTP was longer following CT + RT (7.2 y) than following CT (3.9 y, P = .003) or RT (2.5 y, P<.001) alone but without improved OS; median TTP was longer following treatment with PCV alone than temozolomide alone (7.6 vs. 3.3 y, P = .019). In cases with no deletion, median TTP was longer following CT + RT (3.1 y) than CT (0.9 y, P = .0124) or RT (1.1 y, P < .0001) alone; OS also favored CT + RT (median 5.0 y) over CT (2.2 y, P = .02) or RT (1.9 y, P<.0001) alone. In codeleted cases, CT alone did not appear to shorten OS in comparison with CT + RT, and PCV appeared to offer longer disease control than temozolomide but without a clear survival advantage. Combined CT + RT led to longer disease control and survival than did CT or RT alone in cases with no 1pl9q deletion. Ongoing trials will address these issues prospectively.
机译:对新诊断的间变性少突胶质细胞瘤的治疗存在争议。单独进行放疗(RT)并与化学疗法(CT)结合使用是研究最充分的策略。但是,通常只主张CT,特别是在使用Ipl9q编码的情况下。我们回顾性地确定了从1981年至2007年诊断为1013例成年人,这些成年人最初接受了单独的RT(n = 200),CT + RT(n = 528),单独的CT(«= 201)或其他策略(n = 84)的治疗。中位总生存期(OS)为6.3年,进展时间(TTP)为3.1年。与没有lp或19q删除相比,ipl9q小码删除与更长的OS和TTP相关。在加密码的病例中,CT + RT(7.2 y)后的中位TTP比单独CT(3.9 y,P = .003)或RT(2.5 y,P <.001)后更长,但没有改善OS。单独使用PCV治疗后的中位TTP比单独使用替莫唑胺更长(7.6 vs. 3.3 y,P = .019)。在没有缺失的情况下,CT + RT(3.1 y)后的中位TTP比单独使用CT(0.9 y,P = .0124)或RT(1.1 y,P <.0001)更长。与单独的CT(2.2 y,P = .02)或RT(1.9 y,P <.0001)相比,OS还偏爱CT + RT(中位数5.0 y)。在有代码的病例中,与CT + RT相比,仅CT似乎没有缩短OS,并且PCV似乎比替莫唑胺提供更长的疾病控制时间,但没有明显的生存优势。在没有1pl9q缺失的情况下,与单独使用CT或RT相比,结合使用CT + RT可以更长的疾病控制和生存期。正在进行的试验将有望解决这些问题。

著录项

  • 来源
    《Neuro-Oncology》 |2011年第6期|p.649-659|共11页
  • 作者单位

    Departments of Neurology the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA;

    Departments of Neurology the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA;

    University of California, Los Angeles, Los Angeles, USA;

    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

    Massachusetts General Hospital, Boston, MA, USA;

    Massachusetts General Hospital, Boston, MA, USA;

    NorthShore University HealthSystem,Evanston Hospital Kellogg Cancer Center University of Chicago, Pritzker School of Medicine, Evanston, IL, USA;

    London Regional Cancer Program, London, Ontario, Canada;

    Barrow Neurological Inst,Phoenix, AZ, USA;

    University of Calgary, Calgary, Alberta, Canada;

    University of Calgary, Calgary, Alberta, Canada;

    Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA;

    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Children's Hospital Boston, Brigham and Women's Hospital, Boston, MA, USA;

    University of Virginia Health System, Charlottesville, VA, USA;

    University of Wisconsin, Madison, Wl, USA;

    University of Wisconsin, Madison, Wl, USA;

    University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA;

    Princess Margaret Hospital, Toronto, Ontario, Canada;

    Albany Medical Center, Albany, NY, USA;

    Kaiser Permanente-Los Angeles Medical Center, Los Angeles, CA,USA;

    Clemenceau Medical Center, Beirut, Lebanon and Universite Saint-Esprit de Kaslik, Byblos,Lebanon;

    Departments of Neurology the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA;

    Departments of Neurology the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA;

    Pathology the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA;

    Pathology the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA;

    Epidemiology-Biostatistics , the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    oligodendroglioma; oligo-astrocytoma; pcv; temozolomide; 1pl9q.;

    机译:少突胶质细胞瘤星形细胞瘤pcv;替莫唑胺1pl9q。;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号